MeritValue

VITASPRING BIOMEDICAL CO. LTD.

VSBCdata completeness 75%10 fiscal years on file

Data notes: no data for concept 'totalDebt'; no data for concept 'interestExpense'

The thesis, from the filings

VITASPRING BIOMEDICAL CO. LTD. earns about 58% on equity, with a roughly flat share count. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2022FY 2023FY 2024FY 2025FY 2026
Revenue$5.61M1$02$03$04$04
Net income$909,5605−$4.16M6−$1.12M7−$774,9228−$415,3688
Operating cash flow−$269,6319−$77,55610−$34,92011−$14,67512−$2,68812
Capital expenditure$72,99713$013———
Free cash flow (derived)−$342,6289−$77,55610———
Total debt—————
Cash & equivalents$107,21214$29,65615$016$016$2,08417
Diluted shares206.0M206.5M207.0M207.0M207.0M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.21
your share of equity
Profit it earned you last year
−$0.02
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$0.21 of net worth that earned you −$0.02 last year.

iii. Is this a good business?
Moat signal · return on equity
58% avg · 5y
FY22 58%FY23 —FY24 —FY25 —FY26 —

It earned an average 58% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
+1% shares · 5y

Share count is roughly flat over 5 years — little dilution, little buyback.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2022-01-31 · accession 0001640334-25-002237 (Revenues)
  2. 10-K · period ending 2023-01-31 · accession 0001640334-26-000426 (Revenues)
  3. 10-K · period ending 2024-01-31 · accession 0001640334-26-001019 (Revenues)
  4. 10-K · period ending 2025-01-31 · accession 0001640334-26-001082 (Revenues)
  5. 10-K · period ending 2022-01-31 · accession 0001640334-25-002237 (NetIncomeLoss)
  6. 10-K · period ending 2023-01-31 · accession 0001640334-26-000426 (NetIncomeLoss)
  7. 10-K · period ending 2024-01-31 · accession 0001640334-26-001019 (NetIncomeLoss)
  8. 10-K · period ending 2025-01-31 · accession 0001640334-26-001082 (NetIncomeLoss)
  9. 10-K · period ending 2022-01-31 · accession 0001640334-25-002237 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2023-01-31 · accession 0001640334-26-000426 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2024-01-31 · accession 0001640334-26-001019 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2025-01-31 · accession 0001640334-26-001082 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2022-01-31 · accession 0001640334-25-002237 (PaymentsToAcquirePropertyPlantAndEquipment)
  14. 10-K · period ending 2022-01-31 · accession 0001697884-22-000006 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2023-01-31 · accession 0001640334-26-001019 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
  16. 10-K · period ending 2024-01-31 · accession 0001640334-26-001019 (CashAndCashEquivalentsAtCarryingValue)
  17. 10-K · period ending 2026-01-31 · accession 0001640334-26-001082 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)